e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Asthma: outcomes of clinical trials and cohorts
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
QUALAS: QUAlity of Life and burden in ASthma, a comparison between uncontrolled severe asthma and controlled moderate/severe asthma
A. Bourdin (Montpellier, France), C. Chenivesse (Lille, France), A. Didier (Toulouse, France), C. Touboul (Paris, France), M. (Toulon, France), L. Portel (Libourne, France)
Source:
International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Session:
Asthma: outcomes of clinical trials and cohorts
Session type:
Thematic Poster
Number:
4251
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Bourdin (Montpellier, France), C. Chenivesse (Lille, France), A. Didier (Toulouse, France), C. Touboul (Paris, France), M. (Toulon, France), L. Portel (Libourne, France). QUALAS: QUAlity of Life and burden in ASthma, a comparison between uncontrolled severe asthma and controlled moderate/severe asthma. 4251
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Difficult-to-treat asthma: how serious is the problem and what are the issues?
Source: Eur Respir Mon 2011; 51: 1-15
Year: 2011
Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011
Current burden of uncontrolled asthma in the general population: The OPCRD asthma state of the union study
Source: International Congress 2016 – Asthma and allergy in infancy: from risk factors to mortality
Year: 2016
Factors influencing to HRQOL of patients with mild to moderate persistent asthma in Japan; sub-analysis of GAIA study
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Effect of tralokinumab on GINA control in severe, uncontrolled asthma
Source: International Congress 2017 – Asthma: mechanisms and treatment
Year: 2017
Clinical characteristics and burden of illness in a cohort of severe asthma patients
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016
Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Is sustained control of severe asthma possible? A composite score to assess 1-year of asthma control
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial
Source: International Congress 2016 – Best abstracts in asthma and COPD
Year: 2016
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017
Multi-symptom asthma (MSA) and comorbidities in a cohort of Italian young asthmatic subjects
Source: Annual Congress 2013 –Epidemiology of asthma
Year: 2013
Prevalence of co-morbidities in severe asthma, COPD and overlap syndrome
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial
Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system
Year: 2016
Sleep quality in patients with asthma and COPD
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011
Association of asthma admissions and health related quality of life (HRQoL), asthma control and severity
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016
Baseline symptom scores and future risk of severe exacerbation: The SPARK study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept